Competitive fitness of influenza B viruses possessing E119A and H274Y neuraminidase inhibitor resistance-associated substitutions in ferrets

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Pascua, Philippe Noriel Q ^a   Marathe, Bindumadhav M ^a   Burnham, Andrew J ^b   Vogel, Peter ^a   Webby, Richard J ^a   Webster, Robert G ^a   Govorkova, Elena A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Gryphon Scientific ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEURAMINIDASE E119A; NEURAMINIDASE H274Y; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ANTIGEN; ANTIVIRUS AGENT; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; FERRET; GROWTH RATE; INFLUENZA B VIRUS; MALE; MOLECULAR DYNAMICS; NONHUMAN; REVERSE GENETICS; VIROGENESIS; VIRUS IDENTIFICATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; DOG; DRUG EFFECTS; ENZYMOLOGY; GENETICS; MDCK CELL LINE; MUSTELA PUTORIUS FURO; MUTATION; PATHOGENICITY; PHYSIOLOGY; VIRULENCE;

ANIMALS; ANTIVIRAL AGENTS; DOGS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FERRETS; INFLUENZA B VIRUS; MADIN DARBY CANINE KIDNEY CELLS; MUTATION; NEURAMINIDASE; VIRULENCE; VIRUS REPLICATION;

EID: 84982712636     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159847     Document Type: Article

References (61)

1. Gutierrez-Pizarraya A, Perez-Romero P, Alvarez R, Aydillo TA, Osorio-Gomez G, Milara-Ibanez C, et al. (2012) Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave. JInfect 65: 423-430.
2. Kaji M, Watanabe A, Aizawa H (2003) Differences in clinical features between influenza A H1N1, A H3N2, and B in adult patients. Respirology 8: 231-233. PMID: 12753540
3. McCullers JA, Hayden FG (2012) Fatal influenza B infections: time to reexamine influenza research priorities. JInfectDis 205: 870-872.
4. Sakudo A, Baba K, Ikuta K (2012) Analysis of Vis-NIR spectra changes to measure the inflammatory response in the nasal mucosal region of influenza A and B virus-infected patients. JClinVirol 55: 334-338.
5. Chi CY, Wang SM, Lin CC, Wang HC, Wang JR, Su IJ, et al. (2008) Clinical features of children infected with different strains of influenza B in southern Taiwan. PediatrInfectDisJ 27: 640-645.
6. Li WC, Shih SR, Huang YC, Chen GW, Chang SC, Hsiao MJ, et al. (2008) Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan. JClinVirol 42: 45-51.
7. CDC (2015) FluView: national and regional level outpatient illness and viral surveillance. Centers for Disease Control and Prevention Atlanta, GA.
8. CDC (2015) FluView: influenza-associated pediatric mortality. Centers for Disease Control and Prevention. Atlanta, GA.
9. Burnham AJ, Baranovich T, Govorkova EA (2013) Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res 100: 520-534. doi: 10.1016/j.antiviral.2013.08.023 PMID: 24013000
10. Ambrose CS, Levin MJ (2012) The rationale for quadrivalent influenza vaccines. HumVaccinImmunother 8: 81-88.
11. Barr IG, Jelley LL (2012) The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs 72: 2177-2185. doi: 10.2165/11641110-000000000-00000 PMID: 23110610
12. Colman PM, Varghese JN, Laver WG (1983) Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303: 41-44. PMID: 6188957
13. Nguyen HT, Fry AM, Gubareva LV (2012) Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. AntivirTher 17: 159-173.
14. Samson M, Pizzorno A, Abed Y, Boivin G (2013) Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 98: 174-185. doi: 10.1016/j.antiviral.2013.03.014 PMID: 23523943
15. Domingo E, Menendez-Arias L, Holland JJ (1997) RNA virus fitness. RevMedVirol 7: 87-96.
16. Baranovich T, Webster RG, Govorkova EA (2011) Fitness of neuraminidase inhibitor-resistant influenza A viruses. CurrOpinVirol 1: 574-581.
17. Jackson D, Barclay W, Zurcher T (2005) Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. JAntimicrobChemother 55: 162-169.
18. Burnham AJ, Baranovich T, Marathe BM, Armstrong J, Webster RG, Govorkova EA (2014) Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. AntimicrobAgents Chemother 58: 2718-2730.
19. Belser JA, Katz JM, Tumpey TM (2011) The ferret as a model organism to study influenza A virus infection. DisModelMech 4: 575-579.
20. Maher JA, DeStefano J (2004) The ferret: an animal model to study influenza virus. Lab Anim (NY) 33: 50-53.
21. van RD, Munster VJ, de WE, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, et al. (2007) Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. AmJPathol 171: 1215-1223.
22. Kim YH, Kim HS, Cho SH, Seo SH (2009) Influenza B virus causes milder pathogenesis and weaker inflammatory responses in ferrets than influenza A virus. Viral Immunol 22: 423-430. doi: 10.1089/vim. 2009.0045 PMID: 19951179
23. Huang SS, Banner D, Fang Y, Ng DC, Kanagasabai T, Kelvin DJ, et al. (2011) Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets. PLoSOne 6: e27512.
24. Carolan LA, Rockman S, Borg K, Guarnaccia T, Reading P, Mosse J, et al. (2015) Characterisation of the localised immune response in the respiratory tract of ferrets following infection with influenza A and B viruses. J Virol.
25. Huang SS, Banner D, Paquette SG, Leon AJ, Kelvin AA, Kelvin DJ (2014) Pathogenic influenza B virus in the ferret model establishes lower respiratory tract infection. JGenVirol 95: 2127-2139.
26. Jakeman KJ, Tisdale M, Russell S, Leone A, Sweet C (1994) Efficacy of 2'-deoxy-2'-fluororibosides against influenza A and B viruses in ferrets. AntimicrobAgents Chemother 38: 1864-1867.
27. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG (1998) Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. JInfectDis 178: 1257-1262.
28. Mishin VP, Hayden FG, Gubareva LV (2005) Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. AntimicrobAgents Chemother 49: 4515-4520.
29. Burnham AJ, Armstrong J, Lowen AC, Webster RG, Govorkova EA (2015) Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium. JVirol 89: 4575-4587.
30. Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G (2002) Rescue of influenza B virus from eight plasmids. ProcNatlAcadSciUSA 99: 11411-11416.
31. Matsuoka Y, Lamirande EW, Subbarao K (2009) The ferret model for influenza. CurrProtocMicrobiol Chapter 15: Unit.
32. Reed L, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
33. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG (2007) Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 51: 1414-1424. PMID: 17296744
34. Govorkova EA, Marathe BM, Prevost A, Rehg JE, Webster RG (2011) Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. Antiviral Res 91: 81-88. doi: 10.1016/j.antiviral.2011.05.008 PMID: 21635924
35. Marriott AC, Dove BK, Whittaker CJ, Bruce C, Ryan KA, Bean TJ, et al. (2014) Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir. PLoS One 9: e94090. doi: 10.1371/journal.pone.0094090 PMID: 24709834
36. Mishin VP, Nedyalkova MS, Hayden FG, Gubareva LV (2005) Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model. Vaccine 23: 2922-2927. PMID: 15780741
37. Oh DY, Barr IG, Hurt AC (2015) A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity. PLoS One 10: e0118780. doi: 10.1371/journal.pone. 0118780 PMID: 25738900
38. Panozzo J, Oh DY, Margo K, Morton DA, Piedrafita D, Mosse J, et al. (2015) Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection. Antiviral Res 120: 66-71. doi: 10. 1016/j.antiviral.2015.05.007 PMID: 26022199
39. Sweet C, Macartney JC, Bird RA, Cavanagh D, Collie MH, Husseini RH, et al. (1981) Differential distribution of virus and histological damage in the lower respiratory tract of ferrets infected with influenza viruses of differing virulence. JGenVirol 54: 103-114.
40. Govorkova EA, Ilyushina NA, Marathe BM, McClaren JL, Webster RG (2010) Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model. JVirol 84: 8042-8050.
41. Pinilla LT, Holder BP, Abed Y, Boivin G, Beauchemin CA (2012) The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets. JVirol 86: 10651-10660.
42. Hurt AC, Nor'e SS, McCaw JM, Fryer HR, Mosse J, McLean AR, et al. (2010) Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol 84: 9427-9438. doi: 10.1128/JVI.00373-10 PMID: 20631138
43. Abed Y, Pizzorno A, Bouhy X, Rheaume C, Boivin G (2014) Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets. JVirol 88: 1652-1658.
44. Bloom JD, Gong LI, Baltimore D (2010) Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275. doi: 10.1126/science.1187816 PMID: 20522774
45. Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, et al. (2014) Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoSPathog 10: e1004065.
46. Rameix-Welti MA, Munier S, Le GS, Cuvelier F, Agou F, Enouf V, et al. (2011) Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution. AntivirTher 16: 597-603.
47. Duan S, Boltz DA, Seiler P, Li J, Bragstad K, Nielsen LP, et al. (2010) Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoSPathog 6: e1001022.
48. Duan S, Boltz DA, Seiler P, Li J, Bragstad K, Nielsen LP, et al. (2011) Competitive transmissibility and fitness of oseltamivirsensitive and resistant pandemic influenza H1N1 viruses in ferrets. Influenza Other Respir Viruses 5 Suppl 1: 79-82. PMID: 21751461
49. Seibert CW, Kaminski M, Philipp J, Rubbenstroth D, Albrecht RA, Schwalm F, et al. (2010) Oseltamivirresistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. JVirol 84: 11219-11226.
50. Massin P, van der Werf S, Naffakh N (2001) Residue 627 of PB2 is a determinant of cold sensitivity in RNA replication of avian influenza viruses. JVirol 75: 5398-5404.
51. Stuart-Harris CH (1965) Influenza and other virus infections of the respiratory tract. London: Arnold.
52. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, et al. (2012) Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336: 1534-1541. doi: 10.1126/science. 1213362 PMID: 22723413
53. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y (2006) Avian flu: influenza virus receptors in the human airway. Nature 440: 435-436. PMID: 16554799
54. Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Nguyen T, et al. (2007) Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoSPathog 3: 1374-1379.
55. Marcus PI, Ngunjiri JM, Sekellick MJ (2009) Dynamics of biologically active subpopulations of influenza virus: plaque-forming, noninfectious cell-killing, and defective interfering particles. J Virol 83: 8122-8130. doi: 10.1128/JVI.02680-08 PMID: 19494019
56. Frensing T, Pflugmacher A, Bachmann M, Peschel B, Reichl U (2014) Impact of defective interfering particles on virus replication and antiviral host response in cell culture-based influenza vaccine production. Appl Microbiol Biotechnol 98: 8999-9008. doi: 10.1007/s00253-014-5933-y PMID: 25132064
57. Couceiro JN, Baum LG (1994) Characterization of the hemagglutinin receptor specificity and neuraminidase substrate specificity of clinical isolates of human influenza A viruses. Mem Inst Oswaldo Cruz 89: 587-591. PMID: 8524060
58. Wagner R, Matrosovich M, Klenk HD (2002) Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 12: 159-166. PMID: 11987141
59. Yen HL, Liang CH, Wu CY, Forrest HL, Ferguson A, Choy KT, et al. (2011) Hemagglutinin-neuraminidase balance confers respiratory-droplet transmissibility of the pandemic H1N1 influenza virus in ferrets. Proc Natl Acad Sci U S A 108: 14264-14269. doi: 10.1073/pnas.1111000108 PMID: 21825167
60. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, et al. (2002) The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55: 307-317. PMID: 12103431
61. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, et al. (2006) Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. JVirol 80: 8787-8795.